These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 21171671)

  • 1. Niacin extended release (ER)/simvastatin (Simcor®): a guide to its use in lipid regulation.
    Lyseng-Williamson KA
    Drugs R D; 2010; 10(4):253-60. PubMed ID: 21171671
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term safety and efficacy of a combination of niacin extended release and simvastatin in patients with dyslipidemia: the OCEANS study.
    Karas RH; Kashyap ML; Knopp RH; Keller LH; Bajorunas DR; Davidson MH
    Am J Cardiovasc Drugs; 2008; 8(2):69-81. PubMed ID: 18422390
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of complex lipid abnormalities with a fixed dose combination of simvastatin and extended release niacin.
    Robinson JG
    Vasc Health Risk Manag; 2009; 5(1):31-43. PubMed ID: 19436666
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting multiple dyslipidemias with fixed combinations--focus on extended release niacin and simvastatin.
    Pandian A; Arora A; Sperling LS; Khan BV
    Vasc Health Risk Manag; 2008; 4(5):1001-9. PubMed ID: 19183748
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE]).
    Bays HE; Dujovne CA; McGovern ME; White TE; Kashyap ML; Hutcheson AG; Crouse JR;
    Am J Cardiol; 2003 Mar; 91(6):667-72. PubMed ID: 12633795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Niacin extended-release/simvastatin combination therapy produces larger favorable changes in high-density lipoprotein particles than atorvastatin monotherapy.
    Toth PP; Thakker KM; Jiang P; Padley RJ
    Vasc Health Risk Manag; 2012; 8():39-44. PubMed ID: 22323895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of extended-release niacin/laropiprant added to a stable simvastatin dose in secondary prevention patients not at cholesterol goal in Germany.
    Michailov GV; Davies GM; Krobot KJ
    Eur J Health Econ; 2012 Jun; 13(3):365-74. PubMed ID: 21465286
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of low-dose of niacin associated to simvastatin in the treatment of mixed dyslipidemia Salgad.
    Salgado BJ; Salgado JV; Dos Santos AM; Casulari LA
    Minerva Cardioangiol; 2010 Oct; 58(5):531-42. PubMed ID: 20948500
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Niacin extended-release therapy in phase III clinical trials is associated with relatively low rates of drug discontinuation due to flushing and treatment-related adverse events: a pooled analysis.
    Brinton EA; Kashyap ML; Vo AN; Thakkar RB; Jiang P; Padley RJ
    Am J Cardiovasc Drugs; 2011 Jun; 11(3):179-87. PubMed ID: 21619381
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fixed-dose combination of extended-release niacin plus simvastatin for lipid disorders.
    Vo AN; Kashyap ML
    Expert Rev Cardiovasc Ther; 2008 Nov; 6(10):1303-10. PubMed ID: 19018682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simcor: a niacin/simvastatin combination.
    Med Lett Drugs Ther; 2008 Apr; 50(1283):25-6. PubMed ID: 18391898
    [No Abstract]   [Full Text] [Related]  

  • 12. Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia.
    Guyton JR; Brown BG; Fazio S; Polis A; Tomassini JE; Tershakovec AM
    J Am Coll Cardiol; 2008 Apr; 51(16):1564-72. PubMed ID: 18420099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extended-release niacin (nicotinic acid)/laropiprant.
    Perry CM
    Drugs; 2009 Aug; 69(12):1665-79. PubMed ID: 19678716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety, tolerance, and efficacy of extended-release niacin monotherapy for treating dyslipidemia risks in persons with chronic tetraplegia: a randomized multicenter controlled trial.
    Nash MS; Lewis JE; Dyson-Hudson TA; Szlachcic Y; Yee F; Mendez AJ; Spungen AM; Bauman WA
    Arch Phys Med Rehabil; 2011 Mar; 92(3):399-410. PubMed ID: 21276961
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Niacin extended-release/simvastatin.
    Sanford M; Curran MP
    Drugs; 2008; 68(16):2373-86. PubMed ID: 18973399
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extended-release niacin treatment of the atherogenic lipid profile and lipoprotein(a) in diabetes.
    Pan J; Van JT; Chan E; Kesala RL; Lin M; Charles MA
    Metabolism; 2002 Sep; 51(9):1120-7. PubMed ID: 12200755
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Niacin, an old drug with new perspectives for the management of dyslipidaemia.
    Benhalima K; Muls E
    Acta Clin Belg; 2010; 65(1):23-8. PubMed ID: 20373594
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and tolerability of extended-release niacin with laropiprant.
    Yadav R; Kwok S; Ammori BJ; Issa B; Soran H
    Expert Opin Drug Saf; 2012 Jan; 11(1):151-9. PubMed ID: 22133050
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Once-daily niacin extended release/lovastatin combination tablet has more favorable effects on lipoprotein particle size and subclass distribution than atorvastatin and simvastatin.
    Bays HE; McGovern ME
    Prev Cardiol; 2003; 6(4):179-88. PubMed ID: 14605511
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extended-release niacin/laropiprant: reducing niacin-induced flushing to better realize the benefit of niacin in improving cardiovascular risk factors.
    Paolini JF; Bays HE; Ballantyne CM; Davidson M; Pasternak R; Maccubbin D; Norquist JM; Lai E; Waters MG; Kuznetsova O; Sisk CM; Mitchel YB
    Cardiol Clin; 2008 Nov; 26(4):547-60. PubMed ID: 19031552
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.